Show simple item record

Systems biology and network pharmacology of frailty reveal novel epigenetic targets and mechanisms

dc.rights.licensehttp://creativecommons.org/licenses/by/4.0es_MX
dc.creatorJUAN CARLOS GOMEZ VERJANes_MX
dc.creatorRICARDO RAMIREZ ALDANAes_MX
dc.creatorMARIO ULISES PEREZ ZEPEDAes_MX
dc.creatorRICARDO DAVID QUIROZ BAEZes_MX
dc.creatorARMANDO LUNA LOPEZes_MX
dc.creatorLUIS MIGUEL FRANCISCO GUTIERREZ ROBLEDOes_MX
dc.date2019
dc.date.accessioned2021-08-23T22:46:47Z
dc.date.available2021-08-23T22:46:47Z
dc.identifier.urihttp://repositorio.inger.gob.mx/jspui/handle/20.500.12100/17220
dc.descriptionFrailty is an age-associated condition, characterized by an inappropriate response to stress that results in a higher frequency of adverse outcomes (e.g., mortality, institutionalization and disability). Some light has been shed over its genetic background, but this is still a matter of debate. In the present study, we used network biology to analyze the interactome of frailty-related genes at different levels to relate them with pathways, clinical deficits and drugs with potential therapeutic implications. Significant pathways involved in frailty: apoptosis, proteolysis, muscle proliferation, and inflammation; genes as FN1, APP, CREBBP, EGFR playing a role as hubs and bottlenecks in the interactome network and epigenetic factors as HIST1H3 cluster and miR200 family were also involved. When connecting clinical deficits and genes, we identified five clusters that give insights into the biology of frailty: cancer, glucocorticoid receptor, TNF-α, myostatin, angiotensin converter enzyme, ApoE, interleukine-12 and −18. Finally, when performing network pharmacology analysis of the target nodes, some compounds were identified as potentially therapeutic (e.g., epigallocatechin gallate and antirheumatic agents); while some other substances appeared to be toxicants that may be involved in the development of this condition.es_MX
dc.formatAdobe PDFes_MX
dc.languageenges_MX
dc.publisherNature Researches_MX
dc.relationhttps://www.nature.com/articles/s41598-019-47087-7es_MX
dc.relation.requiresSies_MX
dc.rightsAcceso Abiertoes_MX
dc.sourceScientific Reports (2045-2322) Vol. 9 (2019)es_MX
dc.subjectMEDICINA Y CIENCIAS DE LA SALUDes_MX
dc.subjectCiencias médicases_MX
dc.subjectCiencias clínicases_MX
dc.subjectGeriatríaes_MX
dc.subjectCondiciones patológicas, signos y síntomases_MX
dc.subjectProcesos patológicoses_MX
dc.subjectFragilidades_MX
dc.subjectCrecimiento y desarrolloes_MX
dc.subjectEnvejecimientoes_MX
dc.subjectGeriatricses_MX
dc.subjectPathological conditions, signs and symptomses_MX
dc.subjectPathologic processeses_MX
dc.subjectFrailtyes_MX
dc.subjectGrowth and developmentes_MX
dc.subjectAginges_MX
dc.titleSystems biology and network pharmacology of frailty reveal novel epigenetic targets and mechanismses_MX
dc.typeArtículoes_MX
dc.audienceResearcherses_MX
dc.creator.idGOVJ850305HDFMRN07es_MX
dc.creator.idRAAR780730HDFMLC00es_MX
dc.creator.idPEZM760111HDFRPR07es_MX
dc.creator.idQUBR800502HDFRZC09es_MX
dc.creator.idLULA690630HDFNPR02es_MX
dc.creator.idGURL571005HDFTBS14es_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX
dc.creator.nameIdentifiercurpes_MX


Files in this item

Thumbnail
Name:
Scientific Reports (2045-2322) ...
Size:
4.112Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record